Recent clinical study in advanced gastric cancer patients investigating the safety and efficacy of toriparimab, a newly approved humanized PD-1 antibody, showed that high TMB (12 mt/mb, upper 20 percentile cut-off) was associated with improved patient responses and survival benefit after immunotherapy (18). The gene discussed is PDCD1; the disease is gastric cancer.